WO2015013665A1 - Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics - Google Patents
Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics Download PDFInfo
- Publication number
- WO2015013665A1 WO2015013665A1 PCT/US2014/048277 US2014048277W WO2015013665A1 WO 2015013665 A1 WO2015013665 A1 WO 2015013665A1 US 2014048277 W US2014048277 W US 2014048277W WO 2015013665 A1 WO2015013665 A1 WO 2015013665A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- sar
- linker
- extendin
- analog
- Prior art date
Links
- 206010022498 insulinoma Diseases 0.000 title claims abstract description 24
- 208000021255 pancreatic insulinoma Diseases 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims abstract description 19
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- NVOVSXGZALWAFS-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane Chemical group C1NCCNCC2CNCCNCC1CNCCNC2 NVOVSXGZALWAFS-UHFFFAOYSA-N 0.000 claims abstract description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 5
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 16
- 125000003827 glycol group Chemical group 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 abstract description 9
- 230000004807 localization Effects 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 description 11
- 239000000700 radioactive tracer Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 238000002600 positron emission tomography Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000012879 PET imaging Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- UQQQAKFVWNQYTP-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane-1,8-diamine Chemical compound C1NCCNCC2(N)CNCCNCC1(N)CNCCNC2 UQQQAKFVWNQYTP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010070783 alanyltyrosine Proteins 0.000 description 4
- 108700013553 diamsar chelate Proteins 0.000 description 4
- 238000012634 optical imaging Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- HTQBXNHDCUEHJF-URRANESESA-N exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)C(C)O)C(C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-URRANESESA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001345 alkine derivatives Chemical group 0.000 description 2
- -1 aminomethyl-benzyl modified copper Chemical class 0.000 description 2
- 150000001540 azides Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 description 1
- 101500016415 Lophius americanus Glucagon-like peptide 1 Proteins 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 101000999002 Mus musculus Insulin-1 Proteins 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- UYGBIHFTZHBDEQ-UHFFFAOYSA-N tert-butyl n-[[4-(bromomethyl)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(CBr)C=C1 UYGBIHFTZHBDEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This application relates to a chemical compound for use in multimodality imaging and to the use of the compound in pre- and intra-operative insulinoma and B-cell mass imaging, localization and diagnostics.
- insulinoma is the most common form of cancer of the Islets of Langerhans, the incidence in the general population is only between 1-4 persons/million, making it a rare and unfortunately often neglected form of cancer. The incidence has been reported to be higher in autopsy studies (0.8% to 10%), suggesting that these tumors frequently remain undiagnosed. In most cases, both diagnosis and removal of insulinomas are difficult due to their low signal and noise contrast in different imaging modalities. In addition to that, patients often present with non-specific and/or unclear symptoms leading to ambiguous diagnoses and false positive/negative results. Likewise, the resection of tumor tissue can be difficult in the case of insulinomas, as tumor margins are often not easily delineated.
- the present invention provides a chemical compound that can be used as a multimodality imaging agent.
- the chemical compound has the general formula:
- Ex4 is an extendin-4 analog
- linker is a polyethylene glycol (PEG) chain, for example formed with four ethylene glycol residues;
- Fl is a photoluminescent moiety
- Sar( 4 Cu) is an atom of copper-64 chelated in a sarcophagine moiety.
- the extendin-4 analog is coupled to the Sar(64Cu) via a modification of amino acid 12 in SEQ ID NO: 1.
- a specific extendin-4 analog is shown in SEQ ID NO: 2.
- An exemplary photoluminescent moiety is sulfo-Cy5.
- a specific embodiment of the chemical compound has the structure shown in Fig. 1. This compound is referred to in this application as 64Cu-E4xl2-Sar-Fl.
- the compound of the invention is detectable by optical imaging techniques via the photoluminescent moiety and by imaging techniques that detect the 4 Cu such as positron emission tomography (PET).
- PET positron emission tomography
- the invention further provides for the use of the compound in diagnostic imaging using either or both of the detectable elements.
- the invention further provides a diagnostic method in which a multimodality imaging agent of the invention, for example 64Cu-E4xl2-Sar-Fl, is used to detect insulinoma cells in a patient, including a human patient, by introducing the multimodaility imaging agent into a patient, and detecting the chemical compound by PET imaging, optical detection, or both to determine if insulinoma cells are present.
- the detection can be performed in a diagnostic imaging setting, or for intra-operative tumor detection to localize the tumor to facilitate surgical removal.
- Fig. 1 shows the structure of one specific embodiment of the chemical compound of the invention, 64Cu-E4xl2-Sar-Fl.
- Fig. 2 shows a synthetic scheme for the compound of Fig. 1.
- Fig. 3 shows the excitation and emission spectrum for the compound of the invention, in non-radiolabeled form.
- Fig. 4 shows a procedure for radiolabeling of the compound of Fig. 1 using 4 CuC12. Detailed Description of the Invention
- the present invention provides a new class of multimodal imaging agents that can be used for both PET imaging and intraoperative optical imaging of insulinoma.
- a nuclear and an optical tracer in a single molecule with a targeting moiety we are able to benefit from the unique properties of each modality; PET provides a significantly higher spatial resolution and allows quantitative analysis of radiotracer concentrations and fluorescence imaging provides high-resolution images.
- the attachment of the detectable moieties can alter the binding affinity of the targeting moiety creating a risk that a targeting moiety will become less effective than in the absence of the detection component of the compound.
- the attachment of the detection component could influence the pharmacokinetics of the probe, causing changes in excretion rates leading to extended or shortened blood half-lifes. This can impact the amount of the imaging agent required, as well as the time frame available for performing diagnostics or intra-operative localization.
- Ex4 represents an extendin-4 analog.
- Extendin-4 in a thirty nine amino acid peptide having the sequence set forth in SEQ ID NO: 1.
- the term "extendin-4 analog” refers to a thirty nine residue sequence in which one amino acid is modified to provide a point for linkage of the extendin-4 to the linker.
- the specific residue can be varied, although in specific embodiments, the modified residue is amino acid 12 of SEQ ID NO: 1.
- the nature of the modification to the residue is selected to be compatible with the functionality of the linker to facilitate formation of the bind between the extendin-4 analog and the linker.
- an azide-bearing polyethylenglycol linker was used with an exendin-4 analog bearing a non-natural aminoacid with an alkyne moiety (S)-2-amino-4-pentynoic acid.
- S alkyne moiety
- other modified amino acids can be used to provide reactivity with other functional groups on the linker.
- the "linker” part of the formula comprises functional groups for attachment to the Ex4 and to the Sar moiety in the formula, separated by a polyethylene glycol chain.
- the length of the polyethylene glycol chain can be varied to alter properties such as the half-life of the chemical compound in vivo and the binding affinity of the extendin-4 analog.
- the linker contains 4 polyethylene glycol moieties.
- the Sar( 4 Cu) element in the general formula represents a sarcophagine moiety to which an atom of 4 Cu is chelated.
- a sarcophagine moiety to which an atom of 4 Cu is chelated.
- a sulfo-Cy5 fluorescent tracer Fl.
- the multimodal imaging agent of Fig 1, 64Cu-E4xl2-Sar-Fl was synthesized using the procedure outlined in Figs 2A-D. This procedure is based on established reaction sequences (15-17). Initial evaluation of component parts of the final molecule confirmed the feasibility of the scheme by synthesizing Cu-E4xl2-Sar-Fl, the non- radioactive version of 64Cu-E4xl2-Sar-Fl.
- Sarcophagine (DiAmSar) to attach the fluorescent tracer (sulfo-Cy5), as well as the polyethylenglycol (PEG) linker between the chelator and the biomarker. DiAmSar can also act as a chelator for radioactive copper.
- DiAmSar In the presence of N-Boc-4-(aminomethyl)- benzyl bromide, a highly reactive electrophile carrying a protected primary amine, the DiAmSar is functionalized so that after treatment with trifluoroacetic acid, attachment of the fluorescent tracer and PEG linker was more successful in comparison to previous efforts using aniline derivatives (20).
- the extension of DiAmSar by an aminomethyl-benzyl unit creates a sterically favorable environment for the nucleophilic substitution reaction.
- Fig. 3 shows the specific absorption and emission chromatogram of Cu-E4xl2-Sar-Fl with an absorption maximum of 648 nm and an emission maximum of 660 nm; this is consistent with the literature values for sulfo- Cy5.
- Fig. 4 shows a procedure for radiolabeling of the compound using 64CuC12.
- the chemical compound of the invention including 64Cu-E4xl2-Sar-Fl, fulfills an unmet clinical need. It allows physicians to localize insulinoma tumors even if the size of the tumor is less than 2 cm. Additionally, intra-operative optical imaging during a surgical resection of a tumor can be done with the same drug.
- the compound of the invention including 64Cu-E4xl2-Sar-Fl, can be used to quantify ⁇ cell mass in assessing the magnitude of autoimmune destruction in type 1 diabetes.
- the chemical compounds of the invention provide a modular platform which allows diagnosis and intraoperative optical removal of insulinoma tumors.
- a multimodal imaging system like the one proposed here has a number of advantages over traditionally labeled probes (either PET or fluorescence).
- PET imaging which has become one of the workhorse-technologies in today's clinical practice, intra-operative optical imaging and augmented surgical systems still have to prove their applicability in clinic.
- PBS phosphate-buffered saline
- PET tracers such as 4 Cu allow imaging and detection of tumors macroscopically.
- the additional photoluminescent label allows wide field intra-operative imaging and provides assistance in the identification and surgical resection of tumor tissues.
- the combination of radioactive tracer and photoluminescent label in a single molecule provides the ability to combine deep tissue penetration with high resolution wide field imaging. Intravital high resolution endoscopy allows physicians to quickly identify tumor margins and micro-infiltrates. This is in addition to assisting analysis of surgical margins, which can be provided in real time and on site, since no immunohistochemical staining is required to delineate lesions from healthy tissue.
- HEK-hGLPRlR human embryonic kidney cells were seeded in a 96 well plate (5.5 x 10 4 cells per well) and grown at 37 °C for 48 h. After washing with binding buffer (120 mM NaCl, 1.2 mM MgS0 4 , 13 mM sodium acetate, 5 mM KC1, 1.2 g/L Tris, 2 g/L bovine serum albumin (BSA), and 1.8 g/L glucose, pH 7.6) the cells were cotreated with 30 pM of 125 I-exendin-4 (9-39, PerkinElmer, Boston, MA) and 64Cu-E4xl2-Sar-Fl (final concentration range: 10 "12 -10 "6 M).
- binding buffer 120 mM NaCl, 1.2 mM MgS0 4 , 13 mM sodium acetate, 5 mM KC1, 1.2 g/L Tris, 2 g/L bovine serum albumin (BSA), and 1.8 g/L
- a blood sample was obtained from the great saphenous vein of each animal.
- the radioactivity of the blood samples was recorded with a WIZARD 2 automatic ⁇ -counter from Perkin Elmer and the weights of collected blood samples were determined.
- the percentage of tracer uptake expressed as a percentage injected dose per gram (%ID/g) was calculated as the activity present in the blood weight per actual injected dose, decay-corrected to the time of counting.
- a weighted t 1/2 of 10.1 min was determined.
- the half-life was fitted to a two-phase exponential decay curve, resembling a multicompartment model with a fast agent
- Ahren B Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369-385.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14829114.9A EP3024500A4 (en) | 2014-07-25 | 2014-07-25 | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
US14/889,079 US20160082137A1 (en) | 2013-07-25 | 2014-07-25 | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics |
CN201480042090.9A CN105682690A (en) | 2013-07-25 | 2014-07-25 | Clinical multi-mode tool for insulinoma diagnosis before and in surgery |
PCT/US2014/048277 WO2015013665A1 (en) | 2013-07-25 | 2014-07-25 | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
AU2014292918A AU2014292918A1 (en) | 2013-07-25 | 2014-07-25 | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
JP2016530084A JP2017504563A (en) | 2013-07-25 | 2014-07-25 | Clinical multidisciplinary tool for diagnosis of insulinoma before and during surgery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/858,550 | 2013-07-25 | ||
PCT/US2014/048277 WO2015013665A1 (en) | 2013-07-25 | 2014-07-25 | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015013665A1 true WO2015013665A1 (en) | 2015-01-29 |
Family
ID=59522788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/048277 WO2015013665A1 (en) | 2013-07-25 | 2014-07-25 | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3024500A4 (en) |
WO (1) | WO2015013665A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20100196271A1 (en) * | 2009-01-27 | 2010-08-05 | University Of Southern California | Cage-Like Bifunctional Chelators, Copper-64 Radiopharmaceuticals and PET Imaging Using the Same |
US20110206605A1 (en) * | 2009-12-10 | 2011-08-25 | Kyoto University | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289516B2 (en) * | 2011-03-09 | 2016-03-22 | The General Hospital Corporation | Imaging beta cell mass |
-
2014
- 2014-07-25 EP EP14829114.9A patent/EP3024500A4/en not_active Withdrawn
- 2014-07-25 WO PCT/US2014/048277 patent/WO2015013665A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20100196271A1 (en) * | 2009-01-27 | 2010-08-05 | University Of Southern California | Cage-Like Bifunctional Chelators, Copper-64 Radiopharmaceuticals and PET Imaging Using the Same |
US20110206605A1 (en) * | 2009-12-10 | 2011-08-25 | Kyoto University | Molecular Probe for Imaging of Pancreatic Islets and Use of the Same |
Non-Patent Citations (3)
Title |
---|
CAI, H. ET AL.: "RGD-based PET tracers for imaging receptor integrin a v ? 3 expression", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 56, no. 5, 15 May 2013 (2013-05-15), pages 264 - 279, XP055315360 * |
KIM, T. H. ET AL.: "Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics", BIOCONJUGATE CHEMISTRY, vol. 22, 2011, pages 625 - 632, XP055138198 * |
See also references of EP3024500A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3024500A4 (en) | 2017-04-19 |
EP3024500A1 (en) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wei et al. | Molecular imaging of β-cells: diabetes and beyond | |
JP2023052071A (en) | Tumor and immune cell imaging based on PD-L1 expression | |
Brand et al. | In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent | |
Keliher et al. | Efficient 18F‐labeling of synthetic exendin‐4 analogues for imaging beta cells | |
JPWO2004054978A1 (en) | Quinoline derivatives as diagnostic probes for tau protein storage diseases | |
US20150231284A1 (en) | Molecular probe for imaging of pancreatic islet and the precursor, and use of the same | |
Eriksson et al. | Drug occupancy assessment at the glucose-dependent insulinotropic polypeptide receptor by positron emission tomography | |
KR101511660B1 (en) | Peptide derivative and use thereof | |
US20160082137A1 (en) | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics | |
EP2910945B1 (en) | Molecular probes for imaging of myelin | |
WO2015013665A1 (en) | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics | |
Okarvi et al. | Radiometallo-labeled peptides in tumor diagnosis and targeted radionuclide therapy | |
Cong et al. | Targeted pancreatic beta cell imaging for early diagnosis | |
JP2004067659A (en) | BENZIMIDAZOLE RING-CONTAINING COMPOUND AS DIAGNOSTIC PROBE OF tau-PROTEIN ACCUMULATIVE DISEASE | |
EP2723765B1 (en) | Molecules specifically binding pancreatic beta cells biomarkers | |
Mi et al. | Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with 18F-Al labeled Cys39-exendin-4 | |
Brickute et al. | Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells | |
US20200390913A1 (en) | Radiolabeled progastrin in cancer diagnosis | |
Yue et al. | Evaluation of a novel GLP-1R ligand for PET imaging of prostate cancer | |
RU2811734C2 (en) | Radiolabeled progastrin in cancer diagnosis | |
US20230201382A1 (en) | Radioligands for myelin | |
US20230256120A1 (en) | Diagnostic agent for pancreatic function | |
US20210128756A1 (en) | Radioligands for myelin | |
KR20150102000A (en) | Polypeptide and imaging method | |
Lin | Molecular Imaging of αvβ6–Positive Tumors and Pancreatic β-Cell Mass by Radiolabeled Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14829114 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14889079 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014292918 Country of ref document: AU Date of ref document: 20140725 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016530084 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014829114 Country of ref document: EP |